EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

Flash talks on Real World Evidence

Saturday 01 Jun, 08:30 AM - 10:00 AM Valencia, Spain
Cordoba Flash Talks
08:30
Long-term allergic diseases outcomes in long COVID: multinational population-based cohort studies from South Korea, Japan and the UK
08:37
Long-Term, Real-World Effectiveness of Allergen Immunotherapy in Reducing Infectious Events in Allergic Rhinitis Patients with and without Asthma
08:44
Impact of liquid sublingual immunotherapy with mixed pollen allergens on asthma prevention in polyallergic patients: results from the real-world EfficAPSI study
08:51
Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics
08:58
Real-world study: safety and effectiveness of a subcutaneous glutaraldehyde, polymerized undiluted olive-grasses allergen extract
09:05
Dupilumab Reduces Patient-Reported Cough in Patients with SEA, CRSwNP, and SEA-CRSwNP: a Real-Life Study
09:12
Criteria used by health professionals on the selection of allergen immunotherapy in real clinical practice. CHOICE project results from Interim analysis 2023: PATIENT’S RESULTS
09:19
Effect of sublingual immunotherapy on allergic rhinitis: Real-life data analysis
09:26
How, when and why AIT is prescribed in Italy: a real-life study conducted through a patient association
09:33
Characterization of Patients With Asthma Initiating Dupilumab Treatment in a Real-World Setting: The RAPID Registry
09:40
Real-world effectiveness of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is independent of comorbidities, sinus surgery history and level of type 2 inflammation: Findings from CHRINOSOR

Speakers